Article in Arteriosclerosis, thrombosis, and vascular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Diandra M MastrogiacomoDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-1148-5926
Abbigail PriceDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0009-0006-4118-5824
Yuting FuDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0009-0002-5833-2676
Richa BanerjeeDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-0183-2779
Luz A KnauerDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-9435-7160
Kunyu LiDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).
Ying YangDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-3469-7681
George E DavisDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-1549-1610
Michael T DellingerDepartment of Surgery, Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas (M.T.D.).
Joshua P ScallanDepartment of Molecular Pharmacology and Physiology, University of South Florida, Tampa (D.M.M., A.P., Y.F., R.B., L.A.K., K.L., Y.Y., G.E.D., J.P.S.).ORCID 0000-0002-1190-7308
Funding
TSC Proteins in the Lymphatic VasculatureR01HL166981 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Ying Yang · 2023 to 2026
$2.7M
VEGFR Signaling Controls Lymphatic JunctionsR01HL164825 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI SCALLAN, JOSHUA PAUL · 2022 to 2025
$2.6M
Pathways Regulating Lymphatic Vessel Permeability and Valve FormationR01HL142905 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI SCALLAN, JOSHUA PAUL · 2019 to 2023
$2.2M
Molecular mechanisms enhancing lymphatic valve formationR01HL145397 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI YANG, YING · 2019 to 2023
$1.9M
Training in Research on Vascular Inflammation and InjuryT32HL160529 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI Sarah Y Yuan · 2022 to 2026
$1.1M
Plasminogen Activator Pathway in Lymphatic MalformationsF31HL174150 · NHLBI · UNIVERSITY OF SOUTH FLORIDA · PI MASTROGIACOMO, DIANDRA · 2024 to 2025
backgroundLymphatic malformations are lesions that can be due to inherited or somatic mutations, and they lead to a defective lymphatic vasculature. Activating KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations have been identified recently in patients with lymphatic malformation with lymphedema, chylous ascites, or life-threatening chylothorax. In a lymphatic malformation mouse model, KRAS mutations are associated with a loss of lymphatic valves, which has been proposed to cause chylothorax via retrograde lymph flow into the pleural space. However, the mechanisms underlying the loss of lymphatic valves are unknown.
methodsTo investigate the mechanisms leading to valve loss, we combined the lymphatic-specific and tamoxifen-inducible
resultsOur data showed that lymphatic-specific expression of KRAS-G12D significantly attenuated valve development in the mesentery, diaphragm, and ear skin. Quantitative real-time polymerase chain reaction, Western blot, and gel zymography using human dermal lymphatic endothelial cells expressing KRAS-G12D revealed the upregulation of the PA (plasminogen activator) pathway and MMPs (matrix metalloproteinases). The MMPs were sufficiently activated by plasmin, the product of the PA pathway, in human dermal lymphatic endothelial cells grown in a 3-dimensional collagen matrix, indicating a role for MMPs in the degradation of valve ECM (extracellular matrix) core. Furthermore, a broad-spectrum MMP inhibitor given to
conclusionsWe conclude that hyperactive KRAS signaling upregulates MMPs that become excessively activated by the upregulation of the PA pathway. MMPs then degrade the lymphatic valve ECM core, preventing valve formation.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Lymphatic Malformations With Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. · full record | OpenQuestion